Marie Eve Légaré

Marie Eve Légaré

Auto-generated profile, based on publicly available information

Marie Eve Légaré

McMaster Univ, Div Ophthalmol, Hamilton, ON, Canada

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2024 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
JLJennifer Ling
Jennifer Ling
SYSonia N. Yeung
Sonia N. Yeung
CCClara C. Chan
Clara C. Chan
TTTanya Trinh
Tanya Trinh
FAFares Antaki
Fares Antaki
AIAlfonso Iovieno
Alfonso Iovieno

6 July 2021 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
KFKenjiro Fukushima
Kenjiro Fukushima
RLR. Michael Lappin
R. Michael Lappin
MLMarie Legare
Marie Legare
JVJulia Veir
Julia Veir
Background Information regarding adverse events (AEs) of mycophenolate mofetil (MMF) is limited. Objectives To evaluate the types and frequency of potential AEs of MMF in dogs with immune-mediated disease. Animals One hundred thirty-one dogs treated with MMF for management of suspected immune-mediated disease. Methods Retrospective study. Medical records were reviewed to find and group suspect AEs in gastrointestinal (GI), hematologic, and other categories. Age, dosage, body weight, and sex were analyzed between dogs with and without AEs by using the Mann-Whitney U-test and chi-squared test. Results The median starting dosage of MMF was 17.5 mg/kg/day (interquartile range [IQR] = 15.1-20.6 mg/kg/day) and the median treatment duration was 56 days (IQR = 14-236 days). Mycophenolate mofetil was prescribed for immune-mediated hemolytic anemia (n = 31), immune-mediated thrombocytopenia (n = 31), pemphigus foliaceus (n = 15), immune-mediated polyarthritis (n = 12), and others (n = 42). Overall, potential AEs of MMF were observed in 34 of 131 dogs (GI 24.4% [31/127], neutropenia 4% [3/76], anemia 4% [1/25], thrombocytopenia 4.0% [1/25], and dermatologic 1.5% [2/131]). There were no significant differences among dogs with (n = 37) or without potential AEs (n = 94) in regards to sex, age, body weight, or dosage of MMF (P = .06, .13, .24, and .26, respectively). Conclusions and Clinical Importance In the dogs administered MMF, GI AEs were most common. Since potential hematologic and dermatologic AEs developed in a few dogs, clinicians should be aware of these when prescribing MMF to dogs with immune-mediated disease.

15 July 2021 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Closed access
SQSusan Ruyu Qi
Susan Ruyu Qi
RARoxanne Od Arsenault
Roxanne Od Arsenault
MHMélanie Hébert
Mélanie Hébert
EYEunice You
Eunice You
MLMarie Eve Légaré
Marie Eve Légaré
MMMathieu Mercier
Mathieu Mercier
(max. 250) Purpose: To evaluate the safety and outcomes of immediately sequential bilateral cataract surgery (ISBCS) at a Canadian academic teaching center. Setting: Tertiary university teaching hospital of Laval University, Quebec City, Canada. Design: Retrospective cohort study of 2003 consecutive patients (4006 eyes) who underwent ISBCS under topical anesthesia from January 2019 to December 2019. Methods: All charts were retrospectively reviewed. Outcome measures included intraoperative and postoperative complications, postoperative uncorrected (UCVA) and pinhole (PHVA) visual acuities, and autorefraction measurements. Results: 1218 (60.8%) female and 785 (39.2%) male patients with a mean age of 74 ± 8 years old had a mean preoperative visual acuity of 0.503 LogMAR (Snellen 20/63). The mean axial length was 23.53 ± 1.37 mm. The majority of eyes had monofocal intraocular lenses (IOL) implanted (n=3738, 93.3%) followed by toric (n=226, 5.6%), multifocal (n=25, 0.6%), and multifocal toric (n=17, 0.4%) IOLs. Intraoperative complications included 14 (0.3%) posterior capsule ruptures with 5 (0.1%) requiring sulcus IOL placement, and 7 (0.2%) partial zonulysis, with 3 requiring capsular tension rings (0.07%). There were no cases of endophthalmitis or toxic anterior segment syndrome. Mean 5-week postoperative UCVA was 0.223 (Snellen 20/33), PHVA was 0.153 (Snellen 20/28) with a mean spherical equivalent of -0.21 diopters. Conclusions: ISBCS performed following iSBCS recommended guidelines is a safe procedure. This cohort of 4006 eyes had very few complications, with none attributable to the surgery being done bilaterally. The UCVA, PHVA and refractive outcomes were good.

1 November 2010 in Toxicology Letters
Verified
Journal Article
Closed access
GDGregory P. Dooley
Gregory P. Dooley
Amanda K AshleyAmanda K Ashley
Amanda K Ashley
MLMarie E. Legare
Marie E. Legare
RHRobert J. Handa
Robert J. Handa
WHWilliam H. Hanneman
William H. Hanneman

26 May 2021 in Cornea
Verified
Journal Article
Closed access
SQSusan Ruyu Qi
Susan Ruyu Qi
MHMélanie Md Hébert
Mélanie Md Hébert
EYEunice You
Eunice You
JPJean-Philippe Md Proulx-Gauthier
Jean-Philippe Md Proulx-Gauthier
MLMarie Eve Md Légaré
Marie Eve Md Légaré
Purpose: Ocular manifestations of immunoglobulin G4 (IgG4)-related disease are common in children although remain ill-defined because of the disease's rarity. We describe a pediatric case of IgG4-related orbital disease (IgG4-ROD) who presented with persistent conjunctival infiltration before developing lacrimal gland enlargement 3 years later. Methods: This was a case report. Results: An 8-year-old girl developed forniceal salmon-patch-like conjunctival lesions in her left eye that were refractory to topical corticosteroids. Investigations, including an orbital MRI and 2 conjunctival biopsies, were negative for lymphoma. She was treated with topical corticosteroids and then nonsteroidal antiinflammatory drops. The lesions decreased mildly, and no new lesion emerged. After 3 years, the patient developed a ptosis, new salmon-patch conjunctival lesions, and papillae. Vision deteriorated to 20/80 because of severe punctate epithelial erosions in the left eye, and the Schirmer test was significantly reduced. A repeat MRI revealed an enlarged left lacrimal gland. A biopsy was performed and was compatible with IgG4-ROD. An elevated IgG4 level of 4.61 g/L was also found. The patient was successfully treated with oral prednisone but flared on tapering the dosage. Rituximab was therefore initiated with excellent clinical response, and prednisone was discontinued. Vision returned to 20/20 after aggressive lubrification, punctal plugs, and autologous serum eye drops. Tear function came back to normal, and local treatments were stopped. Conclusions: This case describes a pediatric case of IgG4-ROD presenting initially with conjunctival follicular reaction, later developing lacrimal gland involvement. Therefore, it is important to consider IgG4-ROD in chronic atypical follicular conjunctival lesions in children, even in the absence of orbital disease.

1 August 2021 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
PGPhilippe Gros-Louis
Philippe Gros-Louis
SCStéphane Charest
Stéphane Charest
MLMarie Eve Légaré
Marie Eve Légaré